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Abstract
Resting human CD4 T cells are highly resistant to transfection or infection with lentiviral vectors 
derived from the human immunodeficiency virus (HIV LV). We now describe a flexible and 
efficient approach that permits effective genetic manipulation of these cells while preserving their 
naturally quiescent state. This technology can also be extended to primary lymphoid cultures 
where authentic cellular composition and functional relationships are preserved.
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INTRODUCTION
CD4 T cells play a central role in stimulating adaptive immune responses by interacting with 
various types of immune cells including B cells, cytotoxic T cells, macrophages and 
dendritic cells. Because of their key functions, enhanced CD4 T-cell activity produced by 
genetic mutations, infection, or injury generates pathogenic responses characterized by 
chronic inflammation and hypersensitivity disorders1–3. Conversely, compromised CD4 T-
cell function produces a profound state of immunodeficiency exemplified by the infection 
and depletion of human CD4 T lymphocytes by the human immunodeficiency virus-1 
(HIV-1).
CD4 T cells have been studied primarily in cultures of human peripheral blood because of 
the relative ease of access to this biological fluid. More recently, human lymphoid aggregate 
cultures (HLACs) derived from fresh tonsillar or splenic tissue have also been used for ex 
†Correspondence: wgreene@gladstone.ucsf.edu, Phone: (415) 734-4805, Fax: (415) 355-0153.
*These authors contributed equally to this work.
COMPETING FINANCIAL INTERESTS
The authors declare no conflict of interest.
Supplementary Information accompanies the paper on Gene Therapy website (http://www.nature.com/gt)
HHS Public Access
Author manuscript
Gene Ther. Author manuscript; available in PMC 2014 May 01.
Published in final edited form as:













vivo analysis of CD4 T cell function4. However, a critical limitation in the study of 
quiescent human CD4 T cells is the lack of an experimental system that allows for either the 
efficient knockdown or expression of exogenous genes. A number of viral and non-viral 
(synthetic) methods have been tested including antibody-targeted liposomes5, CD4 aptamer-
siRNA chimeras6, electroporation7, and peptide transduction8. Nevertheless, these synthetic 
approaches have been hampered by low efficiency, direct cell toxicity, or a lack of adequate 
experimental throughput. Retroviral vectors, particularly those derived from lentiviruses 
such as HIV-1 and SIVmac251, are an alternative and more efficient strategy for gene 
delivery to lymphoid cells9. However, lentiviruses are critically limited by their inability to 
infect resting CD4 T cells in peripheral blood and lymphoid tissues. Lentiviral infection is 
often aborted in these cells after viral entry as reverse transcription is initiated but progresses 
with a much slower kinetics that often fail to reach completion10–18. Lentiviral vectors are 
also commonly pseudotyped with the vesicular stomatitis virus glycoprotein G (VSV-G)2, 19 
due to its broad viral tropism. However, in resting CD4 T cells, only CXCR4-tropic HIV 
envelope-mediated entry, but not VSV-G-mediated endocytosis, supports gene delivery by 
lentiviral vectors20, 21. This limitation is attributed to a lack of viral entry via the endocytosis 
pathway, which is active in transformed cells, antigen-presenting cells, and activated CD4 T 
cells, but not in quiescent primary CD4 T cells20.
RESULTS AND DISCUSSION
To relieve the resistance of primary CD4 T cells to HIV LV infection, we used the accessory 
lentiviral gene product protein X (Vpx), which induces proteasomal degradation of 
SAMHD1 in non-permissive human myeloid22 and resting CD4 T cells23, and alleviates 
restriction to HIV-1 in these cells. Vpx is encoded by HIV-2 and its related simian 
immunodeficiency virus (SIV) strains, but not by HIV-1. Vpx molecules were incorporated 
into viral-like particles encoding the core packaging functions of SIVmac251 (Vpx-VLPs), 
as previously described24. These Vpx-VLP particles are non-infectious as they do not 
contain any viral genetic material, but they are used to transiently deliver Vpx into target 
cells where they promote degradation of SAMHD1, thereby rendering the cells permissive 
to HIV LV infection22. In contrast to the commonly used VSV-G glycoprotein, we 
pseudotyped the Vpx-VLPs with the CXCR4-tropic Env of HIV-1, which supports efficient 
fusion of viral particles to quiescent CD4 T lymphocytes20. For the purpose of genetic 
modification, we used a third generation shRNA-encoding HIV LV vector pSico (plasmid 
for Stable RNA interference, conditional)25, bearing a EF1α:mCherry transgene expression 
cassette. The HIV LV particles were also pseudotyped with a CXCR4-tropic Env of HIV-1. 
To achieve productive infection of HIV LV particles, target cells were initially challenged 
with Vpx-VLPs, followed by a second infection with the HIV LV of interest after 24 hours. 
This sequential infection strategy allowed Vpx to establish an optimal permissive state 
within the target cells at the time when the HIV LV infection was performed. To facilitate a 
synchronized delivery of Vpx and fusion of HIV LV particles, cells and particles were 
subjected to high-speed spinoculation at each step (Fig. 1a).
Using these experimental conditions, CD4 T cells were positively isolated from fresh human 
peripheral blood, tonsillar, or splenic tissues, and spinoculated with Vpx-VLPs or empty 
VLPs, followed by infection with HIV LV particles encoding shRNA designed to silence the 
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expression of CD4 (shCD4) or NLRP3 (shNLRP3), versus a non-silencing control 
scrambled sequence (Scramble). Interestingly, spinoculation of Vpx-VLPs efficiently 
abrogated SAMHD1 expression after 48 hours in target CD4 T cells for all of the tissues 
analyzed. It was at this time that HIV LV infection was in progress (Fig. 1b). Of note, at 
longer times (96 and 120 hours), endogenous SAMHD1 expression returned to normal 
levels, likely reflecting protein re-synthesis when cellular Vpx levels decline 
(Supplementary Fig. 1). After 4 days, the abundance of successful HIV LV infections was 
measured by flow cytometry according to the number of CD4 T cells expressing the 
mCherry transgene. Remarkably, spinoculation with Vpx-VLPs dramatically increased the 
number of mCherry-expressing CD4 T cells in all tested tissues (Fig. 1c). Such an increase 
was not observed in cultures spinoculated with empty VLPs, which remained highly 
resistant to HIV LV infection. The background levels of mCherry expression in these 
cultures represent a small fraction of naturally “primed” CD4 T cells that are permissive for 
HIV-1 infection10, 14, 26. Importantly, spinoculation with Vpx-VLPs did not lead to 
activation of resting CD4 T cells or initiation of programmed cell death, as assessed by 
surface expression of the CD69 and CD25 activation markers and Annexin V respectively 
(Fig. 1c, Supplementary Fig. 2). As previously reported27, 28, exogenous supplement of 
deoxynucleosides enhanced shRNA lentiviral delivery to the target cells, but not as 
effectively as spinoculation with Vpx-VLPs (Supplementary Fig. 3). Interestingly, the 
highest fold increase of HIV LV infection was observed in peripheral blood and spleen, 
corresponding to tissues where CD4 T cells exhibit particularly high resistance to lentiviral 
infection (Fig. 1d). Together, these results indicate that the loss of restriction to HIV LV 
infection produced by Vpx-VLPs is not associated with non-specific cellular activation, 
cellular stress promoting apoptosis, or matched by the addition of deoxynucleosides.
We next examined the efficiency of gene silencing by HIV LV particles encoding shRNAs. 
For these experiments, peripheral blood CD4 T cells were spinoculated with Vpx-VLPs and 
infected with either shCD4 or Scramble HIV LV particles. After 4 days, flow cytometry 
analysis revealed a marked decrease of surface CD4 expression among mCherry-positive 
CD4 T cells infected with shCD4 HIV LV particles (Fig. 1e). No decrease in CD4 
expression occurred in either the mCherry-negative cells, or cells infected with Scramble 
HIV LV particles. These results support the conclusion that the decrease in CD4 expression 
reflected shCD4-mediated silencing in the mCherry-positive cells. We next assessed gene 
silencing by shNLRP3 HIV LV particles introduced into tonsillar CD4 T cells. As with 
peripheral blood, pronounced decreases in intracellular NLRP3 mRNA levels and protein 
expression were observed in the mCherry-positive subset of CD4 T cells following infection 
with shNLRP3 HIV LV particles (Fig. 1f). These data demonstrate the efficient and specific 
genetic silencing of resting CD4 T cells by shRNA-coding HIV LV particles. Importantly, 
pseudotyping with CXCR4-tropic HIV-1 Env allowed resting CD4 T cells to be selectively 
targeted for genetic silencing in fresh HLACs containing heterogeneous populations of 
lymphocytes, avoiding the need for prior CD4 T-cell purification (Supplementary Fig. 4).
We next assessed whether the genetic manipulations produced by HIV LV particles were 
sufficient to affect the biological responses occurring within these target cells. We first 
assessed whether infection of shCD4 HIV LV particles inhibits HIV-1 fusion into resting 
blood CD4 T cells. Remarkably, infections with shCD4, but not Scramble HIV LV particles, 
Geng et al. Page 3













significantly reduced the level of HIV-1 fusion into mCherry-positive CD4 T cells (Fig. 2a). 
In contrast, HIV-1 fusion was not inhibited in the mCherry-negative CD4 T cells within the 
same cultures (Fig. 2b), indicating that the observed inhibition was produced by the shCD4-
encoding HIV LV. We next infected tonsillar CD4 T cells with shNLRP3 HIV LV particles 
and assessed their response to nigericin, which specifically engages NLRP3 inflammasome 
promoting caspase-1 activation and cell death29. Treatment with nigericin induced 
pronounced activation of caspase-1 activation in cultures infected with scramble HIV LV, 
including mCherry-positive and negative CD4 T-cells. Strikingly, nigericin treatment failed 
to induce caspase-1 activation in mCherry-positive CD4 T cells receiving the shNLRP3 HIV 
LV particles (Fig. 2c). Further, nigericin no longer induced cell death in these mCherry-
positive CD4 T cells (Fig. 2d, Supplementary Fig. 5).
These findings demonstrate a new and efficient lentivirus-based approach for manipulating 
gene expression in resting CD4 T cells. The use of CXCR4-tropic HIV-1 Env instead of 
VSV-G glycoprotein allows both selective and efficient fusion of lentiviral particles into 
quiescent CD4 T cells without prior mitogen activation or cytokine stimulation. Activation-
rest strategies have been previously used to introduce HIV LV into CD4 T cells, although 
this approach may alter the natural physiology of these cells, skewing them toward a 
memory phenotype and increasing their intrinsic state of activation. The sequential 
spinoculation technique that we employed allows Vpx to establish an optimal permissive 
state in the target cells during the early steps of HIV LV infection. Importantly, this 
permissive state is reversible, as SAMHD1 expression returns to normal levels in the target, 
which likely re-acquire their natural non-permissive state. Such a precise and synchronous 
response may be difficult to achieve without spinoculation (Supplementary Fig. 6)23, 30. 
Importantly, genetic manipulations using HIV LV has been shown with cells of myeloid 
origin30, but not in CD4 T cells from blood and lymphoid tissues, the principal targets of 
HIV-1. This technology could therefore provide a long-sought experimental tool to explore 
key questions in the HIV field involving non-permissive CD4 T cells, including 
investigating the mechanisms underlying the establishment and maintenance of latent HIV 
reservoirs, and identifying the innate sensors that detect abortive HIV DNA reverse 
transcripts in lymphoid CD4 T cells and elicit their cell death10.
MATERIALS AND METHODS
Expression plasmids
SIVmac 251 virus-like particles for Vpx delivery (Vpx-VLPs) were produced using the 
pSIV3+ plasmid, kindly provided by Dr. A. Cimarelli31. The pSIV3+ expression plasmid 
was constructed by replacing the 5′ LTR of SIVmac251 with the CMV promoter and 
enhancer region. The 5′ half of the env gene was also removed, leaving the REV-responsive 
element sequence and the 5′ and 3′ exons of the tat and rev regulatory genes intact. The 3′ 
LTR was replaced by a SV40 polyadenylation sequence, resulting in deletion of the 3′ end 
of the nef gene. Finally, the nef initiation codon was inactivated to prevent translation32. The 
detailed map of this construct is available at: http://www.retrovirology.com/content/5/1/50/
figure/F1?highres=y. To produce empty VLPs, the vpx gene in the pSIV3+ plasmid was 
inactivated by converting its initiation codon to a stop codon to give pSIV3+ΔVpx, kindly 
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provided by Dr. Jacek Skowronski33. Different shRNAs were cloned into modified versions 
of the pSicoR lentiviral vector, which encodes a mCherry reporter driven by an EF-1α 
promoter (pSicoR-mCherry).
Production of Vpx-VLPs and shRNA-coding HIV LV particles
Virus-like particles (VLPs) and HIV-1 lentiviral particles were produced from 293T cells 
using the standard phosphate calcium transfection protocol34. The medium was replaced 
after 16 hours. After 48 hours, the supernatants were collected and clarified by 
sedimentation, and virions were concentrated by ultracentrifugation, and stored at −80°C in 
100% fetal bovine serum. For VLPs, 293T cells were transfected with 8 μg pSIV3+ and 2 μg 
CXCR4-tropic Env (gp160) encoding plasmid (Vpx-VLPs) or with 8 μg PSIV3+ΔVpx and 2 
μg gp160 (Empty VLPs). The amount of VLPs was determined by measuring SIV p27gag 
levels by ELISA assay. shRNA-coding HIV-1 vectors were cloned using a modified version 
of the pSicoR (plasmid for Stable RNA interference, conditional) lentiviral vector25, which 
encodes an mCherry reporter driven by an EF-1α promoter (pSicoR-MS1)35. For cloning of 














To generate the shRNA HIV LV particles, 293T cells were co-transfected with 10μg 
pSicoR-mCherry shRNA constructs, 9μg HIV-based packaging construct NL4-3 8.9136, and 
2μg gp160 encoding plasmids. The lentiviral particle stocks were quantitated by measuring 
p24gag levels by ELISA assay (1 ng p24gag equals approximately 2 × 106 viral particles).
Culture of primary cells
Peripheral blood mononuclear cells (PBMCs) from healthy blood donors (Blood Centers of 
the Pacific, San Francisco, CA) were purified by Ficoll-Hypaque density gradients, followed 
by negative selection with CD14+ microbeads and positive selection with CD4+ microbeads 
(Miltenyi, Bergisch Gladbach, Germany) or negative selection with EasySep Human CD4+ 
T Cell Enrichment Kit (Stemcell) (Supplementary Fig. 7). The purified resting CD4+ T cells 
were cultured in RPMI 1640 medium supplemented with 10% FBS, L-glutamine (2 mM), 
penicillin (50 U/ml), and streptomycin (50 μg/ml). Human tonsil or spleen tissue was 
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obtained from the National Disease Research Interchange and the Cooperative Human 
Tissue Network. Human lymphoid aggregate cultures (HLACs) were prepared using 
tonsillar or splenic tissue as previously described10. CD4 T cells were isolated from HLACs 
by positive selection using CD4 microbeads (Miltenyi) and cultured overnight in 96-well U-
bottomed polystyrene plates (1 X 106 cells/well) in medium (200 μl/well) consisting of 
RPMI 1640 supplemented with 15% heat-inactivated fetal bovine serum, 100 mg/ml 
gentamicin, 200 mg/ml ampicillin, 1 mM sodium pyruvate, 1% nonessential amino acids 
(Mediatech), 2 mM L-glutamine, and 1% fungizone (Invitrogen).
Two-step spinoculation procedure
Fresh CD4 T cells, human aggregate lymphoid cultures (HLAC), or peripheral blood 
lymphocytes (PBLs), were cultured in a V-bottom 96-well plate (1×106 cells/well) and 
chilled on ice for 15 min. Vpx-VLPs pseudotyped with the CXCR4-tropic Env of HIV-1 
were then added (100 ng p24gag/100μl) to each well and mixed with cold cells for an 
additional 15 minutes. The cold temperature allows particle-cell attachment but prevents 
fusion. Particle-coated cells are then tightly packed into a pellet by high-speed centrifugation 
(1200g) for 2 hours at 4°C. This step brings the viral particles in close apposition to the cell 
membranes, promoting a uniform and high level of attachment. Immediately after 
centrifugation cells are cultured at 37°C as a pellet. This step facilitates a coordinated fusion 
of the attached viruses, generating a pulse of virion entry into the target cells. After 24 hours 
at 37°C, Vpx-containing target cells are spinoculated again with shRNA-coding HIV LV 
particles coted with CXCR4-tropic Env of HIV-1 as described above. After 3 days of 
incubation, the cultures are analyzed. Of note, the enhancement by Vpx-VLPs using regular 
infection was not as effective as spinoculation (Supplementary Fig. 6). The background 
levels of mCherry expression in these cultures without Vpx-VLPs enhancement represent a 
small fraction of naturally “primed” CD4 T cells that are permissive for HIV LV infection, 
which can be blocked by reverse transcriptase inhibitor (NNRTI) efavirenz (Supplementary 
Fig. 8).
SAMHD1 protein analysis
CD4 T cells were lysed after 48 hrs VLPs treatment in RIPA buffer (150mM NaCl, 1% 
Nonidet P-40 (vol/vol), 0.5% AB-deoxycholate (vol/vol), 0.1% SDS (vol/vol), 50mM Tris-
HCl (pH 8), 1 mM DTT), and EDTA-free Protease Inhibitor (Roche Applied Science) and 
preceded for SDS-PAGE immunoblotting analysis. The primary antibodies used were 
1/1000 dilution of rabbit polyclonal anti-SAMHD1 (Sigma, Cat # SAB2102077),
FACS analysis and gating strategy
CD4 T cells were washed in FACS buffer (PBS supplemented with 2 mM EDTA and 2% 
fetal bovine serum), stained with APC-conjugated anti-CD4 or anti-CD25/CD69 (all from 
BD Pharmingen) and fixed in 1% paraformaldehyde. Data were collected on a FACS 
Calibur (BD Biosciences) and analyzed with Flowjo software (Treestar). The percentages of 
mCherry(+) CD4 T cells were defined based on uninfected control samples. In some 
experiments, mCherry(+) CD4 T cells were purified by flow cytometry on a FACSAria II 
cell sorter (BD Biosciences). After cell sorting, >99% cells were mCherry positive.
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Total RNA was purified from presorted mCherry(+) CD4 T cells with an RNeasy kit 
(Qiagen). Purified RNA was reverse-transcribed with Oligo(dT)20 and the SuperScript III 
first-stand synthesis system (Invitrogen). Real-time PCR was performed with a QuantiTect 
Probe PCR kit (Qiagen) on a 7900HT fast real-time PCR system (Applied Biosystems). 
Thermal cycling consisted of 15 min denaturation at 95 °C, followed by 50 cycles of 15 s at 
95 °C and 60 s at 60 °C. The data were normalized relative to GAPDH as an endogenous 
control. PCR assays were conducted with predeveloped TaqMan assay primers and probes 
(NLRP3: Hs00918082_m1; GAPDH: Hs03929097_g1; Life Technology).
Intracellular NLRP3 staining
For fixation and antibody staining, tonsil CD4 T cells were seeded in a 96-well V-bottom 
plate at 1 ×106 cells/100 μl/well. Cells were fixed for 60 min at room temperature with 2% 
paraformaldehyde and permeabilized by washing 2 times in 1× BD Perm/Wash buffer (BD 
Biosciences, 554723). Cells were stained with DyLight 488-conjugated anti-NLRP3 
antibody (1:20, Abcam, #ab139884) in 1× BD Perm/Wash buffer at 4°C for 30 minutes in 
the dark. The staining was then monitored by flow cytometry.
Nigericin treatment, cell viability measurement and intracellular caspase-1 activation
For stimulating the pyroptosis death pathway, tonsil CD4 T cells were treated with 5μM 
nigericin (Sigma, Cat. # N7143) for 12 h at 37°C. The potassium ionophore nigericin 
mediates an electroneutral exchange of intracellular K+ ions for extracellular protons, 
providing a second inflammatory stimulus, which results in the NLRP3-mediated activation 
of caspase-1. After 12hrs the cells were collected and assessed for cell viability and levels of 
caspase-1 activity. To determine the cell viability, a standard number of fluorescent beads 
(Flow-Count Fluorospheres, Beckman Coulter) were added to each cell-suspension sample 
before data acquisition. The cell-suspension samples were analyzed using flow cytometry. 
The relative cell viability is normalized based on the number of fluorescent beads acquired. 
To determine intracellular activation of caspase-1, Fluorescent Labeled Inhibitors of 
Caspases (FLICA) probe assays (ImmunoChemistry Technologies #9122) were performed. 
FLICA probes were added directly to the cell culture media, incubated for 15 min at 37°C, 
and washed five times with PBS supplemented with 2 mM EDTA and 2% fetal bovine 
serum. FLICA probes are cell-permeable and covalently bind to the active caspase-1. After 
washing, FLICA fluorescent signal is specifically retained within cells containing active 
caspase-1 while the reagent is washed away in cells lacking active caspase-1.
HIV virion-based fusion assay
The HIV virion-based fusion assay was performed as previously described37. Briefly, 
resting CD4+ T cells (1 × 106) were incubated with BlaM-Vpr containing virions (100 ng of 
p24gag) at 37°C for 2 hr, washed in CO2-independent medium (Gibco BRL), and loaded 
with CCF2/AM dye as described by the manufacturer (Invitrogen). 2 ml of CCF2/AM (1 
mM) was mixed with 8 ml of 0.1% acetic acid containing 100 mg/ml Pluronic-F127R and 
1ml of RPMI to constitute the loading solution. Cells were incubated in 100 ml of loading 
solution for 1 hr at room temperature. After two washes with RPMI, the BlaM reaction was 
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conducted for 16 h at room temperature in 200 ml of CO2 independent media supplemented 
with 10% FBS and 2.5 mM probenecid, a nonspecific inhibitor of anion transport (Sigma 
Pharmaceuticals). Finally, the cells were washed once in RPMI and fixed in a 2% solution of 
paraformaldehyde. The change in emission fluorescence of CCF2 after cleavage by the 
BlaM-Vpr chimera was monitored by flow cytometry with LSR2 (Becton Dickinson, San 
Jose, CA). Data were collected with DiVa software and analyzed with FlowJo software 
(Treestar, San Carlos, CA).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Genetic manipulation of resting CD4 T cells by lentiviral vectors using sequential 
spinoculation of Vpx-VLP and shRNA-encoding HIV LV particles. (a) The spinoculation 
procedure. Fresh target cells were spinoculated with Vpx-VLPs, followed by shRNA-
encoding HIV LV particles. Particles were pseudotyped with the CXCR4-tropic Env of 
HIV-1, which supports efficient fusion of virions to resting CD4 T cells. A detailed 
description is available in the Methods section (b) Spinoculation of Vpx-VLPs degrades 
SAMHD1 in resting CD4 T cells isolated from peripheral blood, tonsil, or spleen after 24 
hours. (c) Efficient infection of resting CD4 T cells by three independent HIV LV particles 
indicated by mCherry transgene expression. Cells expressing mCherry remained viable 
(Supplementary Fig. 2) and negative for CD25/CD69 activation markers as indicated. (d) 
Fold increase of HIV LV infection after spinoculation with Vpx-VLPs as observed in CD4 T 
cells from peripheral blood, tonsil and spleen. (e) A marked decrease of surface CD4 
expression in blood CD4 T cells productively infected with shCD4 HIV LV particles. (f) 
Reduced intracellular NLRP3 mRNA and protein expression in mCherry-positive CD4 T 
cells after infection with shNLRP3 HIV LV particles. Note that CD4 and NLRP3 expression 
were not reduced in mCherry-negative CD4 T cell populations. These data are representative 
of four independent experiments performed using CD4 T cells from peripheral blood, tonsil 
and spleen from four different donors.
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Modulating specific CD4 T cells responses by HIV LV (a, b) Infection of shCD4 HIV LV 
impedes HIV-1 fusion to resting CD4 T cells isolated from blood. To test the ability of 
HIV-1 to fuse with infected cells, we used an HIV virion-based fusion assay that measures 
β-lactamase (BlaM) activity delivered to target cells upon the fusion of X4-tropic NL4-3 
strain of HIV-1 containing BlaM fused to the Vpr protein (BlaM-Vpr-NL4-3)37. Inhibition 
of fusion was specifically observed in the mCherry-positive (a), but not in the mCherry-
negative cells (b) residing in the same cultures. (c) Infection of shNLRP3 HIV LV blocks 
caspase-1 activation in tonsillar CD4 T cells treated with nigericin. (d) Infections with 
shNLRP3 HIV LV prevent caspase-1-mediated death of mCherry-positive CD4 T cells 
treated with nigericin. Inhibition of cell death was not inhibited by mCherry-positive 
Scramble HIV LV.
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